FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2605462664> ?p ?o ?g. }

• W2605462664 endingPage "686" @default.
• W2605462664 startingPage "686" @default.
• W2605462664 abstract "Importance YARS2mutations have been associated with a clinical triad of myopathy, lactic acidosis, and sideroblastic anemia in predominantly Middle Eastern populations. However, the identification of new patients expands the clinical and molecular spectrum of mitochondrial disorders. Objectives To review the clinical, molecular, and genetic features ofYARS2-related mitochondrial disease and to demonstrate a new Scottish founder variant. Design, Setting, and Participants An observational case series study was conducted at a national diagnostic center for mitochondrial disease in Newcastle upon Tyne, England, and review of cases published in the literature. Six adults in a well-defined mitochondrial disease cohort and 11 additional cases described in the literature were identified withYARS2variants between January 1, 2000, and January 31, 2015. Main Outcome and Measures The spectrum of clinical features and disease progression in unreported and reported patients with pathogenicYARS2variants. Results Seventeen patients (median [interquartile range] age at onset, 1.5 [9.8] years) withYARS2-related mitochondrial myopathy were identified. Fifteen individuals (88%) exhibited an elevated blood lactate level accompanied by generalized myopathy; only 12 patients (71%) manifested with sideroblastic anemia. Hypertrophic cardiomyopathy (9 [53%]) and respiratory insufficiency (8 [47%]) were also prominent clinical features. Central nervous system involvement was rare. Muscle studies showed global cytochrome-coxidase deficiency in all patients tested and severe, combined respiratory chain complex activity deficiencies. Microsatellite genotyping demonstrated a common founder effect shared between 3 Scottish patients with a p.Leu392Ser variant. Immunoblotting from fibroblasts and myoblasts of an affected Scottish patient showed normal YARS2 protein levels and mild respiratory chain complex defects. Yeast modeling of novel missenseYARS2variants closely correlated with the severity of clinical phenotypes. Conclusions and Relevance The p.Leu392Ser variant is likely a newly identified founderYARS2mutation. Testing for pathogenicYARS2variants should be considered in patients presenting with mitochondrial myopathy, characterized by exercise intolerance and muscle weakness even in the absence of sideroblastic anemia irrespective of ethnicity. Regular surveillance and early treatment for cardiomyopathy and respiratory muscle weakness is advocated because early treatment may mitigate the significant morbidity and mortality associated with this genetic disorder." @default.
• W2605462664 created "2017-04-28" @default.
• W2605462664 creator A5006400472 @default.
• W2605462664 creator A5011228927 @default.
• W2605462664 creator A5018057407 @default.
• W2605462664 creator A5026606868 @default.
• W2605462664 creator A5030558328 @default.
• W2605462664 creator A5031658824 @default.
• W2605462664 creator A5037897580 @default.
• W2605462664 creator A5039803629 @default.
• W2605462664 creator A5039960400 @default.
• W2605462664 creator A5044816818 @default.
• W2605462664 creator A5045832983 @default.
• W2605462664 creator A5046288998 @default.
• W2605462664 creator A5053378540 @default.
• W2605462664 creator A5053767923 @default.
• W2605462664 creator A5054486997 @default.
• W2605462664 creator A5060930132 @default.
• W2605462664 creator A5066631526 @default.
• W2605462664 creator A5067436636 @default.
• W2605462664 creator A5067866696 @default.
• W2605462664 creator A5068210830 @default.
• W2605462664 creator A5070009054 @default.
• W2605462664 creator A5072736652 @default.
• W2605462664 creator A5076190626 @default.
• W2605462664 creator A5076567939 @default.
• W2605462664 creator A5080807020 @default.
• W2605462664 date "2017-06-01" @default.
• W2605462664 modified "2023-10-13" @default.
• W2605462664 title "Clinical Features, Molecular Heterogeneity, and Prognostic Implications in <i>YARS2</i>-Related Mitochondrial Myopathy" @default.
• W2605462664 cites W1483634883 @default.
• W2605462664 cites W1515247384 @default.
• W2605462664 cites W1521947818 @default.
• W2605462664 cites W1584721347 @default.
• W2605462664 cites W1964357702 @default.
• W2605462664 cites W1965092625 @default.
• W2605462664 cites W1968342930 @default.
• W2605462664 cites W1981801074 @default.
• W2605462664 cites W1983353424 @default.
• W2605462664 cites W1995152144 @default.
• W2605462664 cites W1998364981 @default.
• W2605462664 cites W2009272245 @default.
• W2605462664 cites W2012645980 @default.
• W2605462664 cites W2015357002 @default.
• W2605462664 cites W2017892056 @default.
• W2605462664 cites W2018086090 @default.
• W2605462664 cites W2022312470 @default.
• W2605462664 cites W2025681913 @default.
• W2605462664 cites W2032074640 @default.
• W2605462664 cites W2032628875 @default.
• W2605462664 cites W2036963968 @default.
• W2605462664 cites W2037764582 @default.
• W2605462664 cites W2053274457 @default.
• W2605462664 cites W2053633780 @default.
• W2605462664 cites W2063279494 @default.
• W2605462664 cites W2068018422 @default.
• W2605462664 cites W2070290687 @default.
• W2605462664 cites W2073505231 @default.
• W2605462664 cites W2076647856 @default.
• W2605462664 cites W2076781430 @default.
• W2605462664 cites W2079226610 @default.
• W2605462664 cites W2090671379 @default.
• W2605462664 cites W2095051920 @default.
• W2605462664 cites W2097270551 @default.
• W2605462664 cites W2102270499 @default.
• W2605462664 cites W2109733885 @default.
• W2605462664 cites W2114545533 @default.
• W2605462664 cites W2115989246 @default.
• W2605462664 cites W2121621332 @default.
• W2605462664 cites W2126958666 @default.
• W2605462664 cites W2129011458 @default.
• W2605462664 cites W2134507595 @default.
• W2605462664 cites W2140483630 @default.
• W2605462664 cites W2146368451 @default.
• W2605462664 cites W2147056655 @default.
• W2605462664 cites W2158145450 @default.
• W2605462664 cites W2162098634 @default.
• W2605462664 cites W2163378098 @default.
• W2605462664 cites W2250355798 @default.
• W2605462664 cites W2471372044 @default.
• W2605462664 cites W2497721881 @default.
• W2605462664 doi "https://doi.org/10.1001/jamaneurol.2016.4357" @default.
• W2605462664 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5822212" @default.
• W2605462664 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28395030" @default.
• W2605462664 hasPublicationYear "2017" @default.
• W2605462664 type Work @default.
• W2605462664 sameAs 2605462664 @default.
• W2605462664 citedByCount "38" @default.
• W2605462664 countsByYear W26054626642017 @default.
• W2605462664 countsByYear W26054626642018 @default.
• W2605462664 countsByYear W26054626642019 @default.
• W2605462664 countsByYear W26054626642020 @default.
• W2605462664 countsByYear W26054626642021 @default.
• W2605462664 countsByYear W26054626642022 @default.
• W2605462664 countsByYear W26054626642023 @default.
• W2605462664 crossrefType "journal-article" @default.
• W2605462664 hasAuthorship W2605462664A5006400472 @default.
• W2605462664 hasAuthorship W2605462664A5011228927 @default.

• next